{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:18:54Z","timestamp":1793647134790,"version":"4.5.1"},"reference-count":52,"publisher":"Becaris Publishing Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            We aimed to identify variables that affect the prognosis and treatment effect in multiple myeloma (MM).\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Published literature of randomized controlled trials (RCTs) and population-adjusted indirect comparisons (PAICs) in newly diagnosed (ND) and relapsed\/refractory (RR) MM populations reporting overall survival (OS) and progression-free survival (PFS) were identified. Possible treatment effect modifiers (TEMs) were evaluated based on the ratio between effect estimates of different strata within subgroups for OS and PFS among eligible RCTs. Potential prognostic factors (PFs) were identified using the lists of covariates adjusted for in PAICs meeting the eligibility criteria.\n            <jats:bold>Results:<\/jats:bold>\n            Sixty-five RCTs and 59 PAICs were included for synthesis. In ND-MM and RR-MM patients, age, sex, International Staging System stage, and cytogenetics were identified as potential TEMs for PFS based on data from published RCTs. Refractory disease, prior therapy exposure status and creatinine clearance were additional TEMs for PFS in RR-MM patients. Eastern Cooperative Oncology Group performance score and creatinine clearance were TEM candidates of PFS for ND-MM stem-cell transplant-ineligible patients. No consistent TEMs for OS were identified across all MM populations. Commonly adjusted variables for both OS and PFS in published PAICs of all populations aligned with potential TEMs of PFS identified in published RCTs. Additionally, subtype of MM, time since diagnosis and extramedullary disease or presence of plasmacytoma were common variables for adjustment in PAICs evaluating RR-MM. Frequency of each variable adjusted for differs by population and outcome. Only one PAIC reported TEMs separately from PFs.\n            <jats:bold>Conclusion:<\/jats:bold>\n            TEMs and PFs identified herein can help inform future clinical trial design and serve as a primer when conducting PAICs evaluating OS and PFS in ND\/RR-MM.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0180","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T14:54:36Z","timestamp":1755010476000},"source":"Crossref","is-referenced-by-count":1,"title":["Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-3713","authenticated-orcid":false,"given":"Jianming","family":"He","sequence":"first","affiliation":[{"name":"Johnson and Johnson, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4972-7537","authenticated-orcid":false,"given":"Karen","family":"Chiang","sequence":"additional","affiliation":[{"name":"EVERSANA\u2122, ON L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwu","family":"Lin","sequence":"additional","affiliation":[{"name":"Johnson and Johnson, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winghan Jacqueline","family":"Kwong","sequence":"additional","affiliation":[{"name":"Johnson and Johnson, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5423-0800","authenticated-orcid":false,"given":"John","family":"Maringwa","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics, Johnson and Johnson, Breda, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-7848","authenticated-orcid":false,"given":"Lingfeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Johnson and Johnson, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Nair","sequence":"additional","affiliation":[{"name":"Johnson and Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hashim","sequence":"additional","affiliation":[{"name":"Johnson and Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5979-1706","authenticated-orcid":false,"given":"Mi Jun","family":"Keng","sequence":"additional","affiliation":[{"name":"Johnson and Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1415-8055","authenticated-orcid":false,"given":"Imtiaz A","family":"Samjoo","sequence":"additional","affiliation":[{"name":"EVERSANA\u2122, ON L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"9","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar SV","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99(9), 1802\u20131824 (2024).","journal-title":"Am. J. Hematol."},{"issue":"8","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay JA-O","year":"2019","unstructured":"Ferlay JA-O, Colombet M, Soerjomataram I Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144(8), 1941\u20131953 (2019).","journal-title":"Int. J. Cancer"},{"key":"e_1_3_9_5_2","volume-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay J","unstructured":"Ferlay J, Ervik M, Lam F Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, France. Available from: https:\/\/gco.iarc.who.int\/today"},{"key":"e_1_3_9_6_2","unstructured":"National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Program. Cancer Stat Facts: myeloma [updated 2025]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"e245004","DOI":"10.6004\/jnccn.2024.5004","article-title":"Updates to the management of multiple myeloma","volume":"22","author":"Callander NS","year":"2024","unstructured":"Callander NS, Kumar SK. Updates to the management of multiple myeloma. J. Natl Compr. Canc. Netw. 22(Suppl.), e245004 (2024).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"e_1_3_9_8_2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): multiple myeloma version 2.2026. (2025). Available from: www.nccn.org\/guidelines\/"},{"issue":"2","key":"e_1_3_9_9_2","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Hemasphere 5(2), e528 (2021).","journal-title":"Hemasphere"},{"key":"e_1_3_9_10_2","unstructured":"FDA. Oncology (cancer) \/ hematologic malignancies approval notifications [updated July 2 2025]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancer-hematologic-malignancies-approval-notifications"},{"issue":"9","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jval.2024.05.015","article-title":"A targeted review of worldwide indirect treatment comparison (ITC) guidelines and best practices","volume":"27","author":"Tanaka S","year":"2024","unstructured":"Tanaka S, Igarashi A, De Moor R A targeted review of worldwide indirect treatment comparison (ITC) guidelines and best practices. Value Health 27(9), 1179\u20131190 (2024).","journal-title":"Value Health"},{"issue":"5","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias S","year":"2013","unstructured":"Dias S, Sutton AJ, Ades A, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med. Decis. Making 33(5), 607\u2013617 (2013).","journal-title":"Med. Decis. Making"},{"key":"e_1_3_9_13_2","volume-title":"NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE","author":"Phillippo D","year":"2016","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. NICE Decision Support Unit, UK (2016)."},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1747998"},{"issue":"4","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jval.2019.11.003","article-title":"Critical appraisal of published indirect comparisons and network meta-analyses of competing interventions for multiple myeloma","volume":"23","author":"Cope S","year":"2020","unstructured":"Cope S, Toor K, Popoff E Critical appraisal of published indirect comparisons and network meta-analyses of competing interventions for multiple myeloma. Value Health 23(4), 441\u2013450 (2020).","journal-title":"Value Health"},{"issue":"2","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200\u2013211 (2018).","journal-title":"Med. Decis. Making"},{"issue":"25","key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin PC","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28(25), 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"issue":"30","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin PC","year":"2016","unstructured":"Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat. Med. 35(30), 5642\u20135655 (2016).","journal-title":"Stat. Med."},{"issue":"3","key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/rssa.12579","article-title":"Multilevel network meta-regression for population-adjusted treatment comparisons","volume":"183","author":"Phillippo DM","year":"2020","unstructured":"Phillippo DM, Dias S, Ades AE Multilevel network meta-regression for population-adjusted treatment comparisons. JR Stat. Soc. Ser. A Stat. Soc. 183(3), 1189\u20131210 (2020).","journal-title":"JR Stat. Soc. Ser. A Stat. Soc."},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0046"},{"issue":"1","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjebm-2022-112091","article-title":"Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health","volume":"29","author":"Vanier A","year":"2024","unstructured":"Vanier A, Fernandez JA-O, Kelley S Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health. BMJ Evid. Based Med. 29(1), 1\u20135 (2024).","journal-title":"BMJ Evid. Based Med."},{"issue":"3","key":"e_1_3_9_22_2","doi-asserted-by":"crossref","first-page":"e9426734","DOI":"10.1097\/01.HS9.0000975152.94267.34","article-title":"PB2090: systematic literature review of prognostic factors for relapsed\/refractory multiple myeloma","volume":"7","author":"Kumar S","year":"2023","unstructured":"Kumar S, Leleu X, Weisel K PB2090: systematic literature review of prognostic factors for relapsed\/refractory multiple myeloma. Hemasphere 7(Suppl. 3), e9426734 (2023).","journal-title":"Hemasphere"},{"issue":"12","key":"e_1_3_9_23_2","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jval.2023.09.125","article-title":"CO53: a review of treatment effect modifiers and\/or prognostic factors included in unanchored indirect treatment comparisons (ITCs) Involving triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM)","volume":"26","author":"Towle K","year":"2023","unstructured":"Towle K, Caisip C, Karampampa K, Cope S, Dhanda D. CO53: a review of treatment effect modifiers and\/or prognostic factors included in unanchored indirect treatment comparisons (ITCs) Involving triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM). Value Health 26(12), S23\u2013S24 (2023).","journal-title":"Value Health"},{"key":"e_1_3_9_24_2","article-title":"Ranking the importance of prognostic factors for relapsed\/refractory multiple myeloma: International physician panel consensus following a systematic literature review","author":"Kumar S","year":"2025","unstructured":"Kumar S, Leleu X, Weisel KC Ranking the importance of prognostic factors for relapsed\/refractory multiple myeloma: International physician panel consensus following a systematic literature review. Clin. Lymphoma Myeloma Leuk. doi: 10.1016\/j.clml.2025.03.013 (2025) (Epub ahead of print).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"e_1_3_9_25_2","volume-title":"Bookshelf overview","author":"Bookshelf Overview","year":"2010","unstructured":"Bookshelf Overview. Bookshelf overview. National Center for Biotechnology Information, MD, USA (2010). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554850\/"},{"key":"e_1_3_9_26_2","unstructured":"Higgins JPT Thomas J Chandler J Cochrane handbook for systematic reviews of interventions version 6.5 [updated August 22 2024]. Cochrane. (2024). Available from: www.cochrane.org\/handbook"},{"issue":"7","key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7), e1000097 (2009).","journal-title":"PLoS Med."},{"key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jclinepi.2021.03.009","article-title":"Effect modifiers and statistical tests for interaction in randomized trials","volume":"134","author":"Christensen R","year":"2021","unstructured":"Christensen R, Bours MJL, Nielsen SM. Effect modifiers and statistical tests for interaction in randomized trials. J. Clin. Epidemiol. 134, 174\u2013177 (2021).","journal-title":"J. Clin. Epidemiol."},{"issue":"6","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/cpt.2247","article-title":"Prognostic factors and treatment-effect modifiers in spinal muscular atrophy","volume":"110","author":"Baranello G","year":"2021","unstructured":"Baranello G, Gorni K, Daigl M Prognostic factors and treatment-effect modifiers in spinal muscular atrophy. Clin. Pharmacol. Ther. 110(6), 1435\u20131454 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence technology appraisals","volume":"35","author":"Phillippo DM","year":"2019","unstructured":"Phillippo DM, Dias S, Elsada A, Ades AE, Welton NJ. Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence technology appraisals. Int. J. Technol. Assess. Health Care 35(3), 221\u2013228 (2019).","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"11","key":"e_1_3_9_31_2","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1007\/s12325-021-01884-7","article-title":"DREAMM-2: indirect comparisons of belantamab mafodotin vs. selinexor + dexamethasone and standard of care treatments in relapsed\/refractory multiple myeloma","volume":"38","author":"Prawitz T","year":"2021","unstructured":"Prawitz T, Popat R, Suvannasankha A DREAMM-2: indirect comparisons of belantamab mafodotin vs. selinexor + dexamethasone and standard of care treatments in relapsed\/refractory multiple myeloma. Adv. Ther. 38(11), 5501\u20135518 (2021).","journal-title":"Adv. Ther."},{"issue":"2","key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, Phase III trial","volume":"24","author":"Dytfeld D","year":"2023","unstructured":"Dytfeld D, Wr\u00f3bel T, Jamroziak K Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, Phase III trial. Lancet Oncol. 24(2), 139\u2013150 (2023).","journal-title":"Lancet Oncol."},{"issue":"12","key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","article-title":"Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, Phase III trial","volume":"6","author":"Jackson GH","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, Phase III trial. Lancet Haematol. 6(12), e616\u2013e629 (2019).","journal-title":"Lancet Haematol."},{"issue":"6","key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, Phase III study","volume":"7","author":"Cavo M","year":"2020","unstructured":"Cavo M, Gay F, Beksac M Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, Phase III study. Lancet Haematol. 7(6), e456\u2013e468 (2020).","journal-title":"Lancet Haematol."},{"issue":"2","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson PG","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl. J. Med. 387(2), 132\u2013147 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_9_36_2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, Phase III trial","volume":"22","author":"Moreau P","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, Phase III trial. Lancet Oncol. 22(10), 1378\u20131390 (2021).","journal-title":"Lancet Oncol."},{"issue":"10192","key":"e_1_3_9_37_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, Phase III study","volume":"394","author":"Moreau P","year":"2019","unstructured":"Moreau P, Attal M, Hulin C Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, Phase III study. Lancet 394(10192), 29\u201338 (2019).","journal-title":"Lancet"},{"issue":"11","key":"e_1_3_9_38_2","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, Phase III trial","volume":"22","author":"Facon T","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, Phase III trial. Lancet Oncol. 22(11), 1582\u20131596 (2021).","journal-title":"Lancet Oncol."},{"issue":"6","key":"e_1_3_9_39_2","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, Phase III trial","volume":"9","author":"Dimopoulos MA","year":"2022","unstructured":"Dimopoulos MA, Richardson PG, Bahlis NJ Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, Phase III trial. Lancet Haematol. 9(6), e403\u2013e414 (2022).","journal-title":"Lancet Haematol."},{"issue":"4","key":"e_1_3_9_40_2","doi-asserted-by":"crossref","first-page":"e0153010","DOI":"10.1371\/journal.pone.0153010","article-title":"Quantification of treatment effect modification on both an additive and multiplicative scale","volume":"11","author":"Girerd N","year":"2016","unstructured":"Girerd N, Rabilloud M, Pibarot P, Mathieu P, Roy P. Quantification of treatment effect modification on both an additive and multiplicative scale. PloS ONE 11(4), e0153010 (2016).","journal-title":"PloS ONE"},{"issue":"7","key":"e_1_3_9_41_2","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3324\/haematol.2013.098608","article-title":"Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients","volume":"99","author":"Chretien ML","year":"2014","unstructured":"Chretien ML, Hebraud B, Cances-Lauwers V Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. Haematologica 99(7), 1236\u20131238 (2014).","journal-title":"Haematologica"},{"issue":"6","key":"e_1_3_9_42_2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.bbmt.2019.11.028","article-title":"age is a prognostic factor for the overall survival of patients with multiple myeloma undergoing upfront autologous hematopoietic stem cell transplantation","volume":"26","author":"Cordas Dos Santos DM","year":"2020","unstructured":"Cordas Dos Santos DM, Saliba RM, Patel R age is a prognostic factor for the overall survival of patients with multiple myeloma undergoing upfront autologous hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 26(6), 1077\u20131083 (2020).","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"10","key":"e_1_3_9_43_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.clml.2021.04.013","article-title":"Sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the Myeloma XI Trial","volume":"21","author":"Bird S","year":"2021","unstructured":"Bird S, Cairns D, Menzies T Sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the Myeloma XI Trial. Clin. Lymphoma Myeloma Leuk. 21(10), 667\u2013675 (2021).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"15","key":"e_1_3_9_44_2","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp PR","year":"2005","unstructured":"Greipp PR, Miguel JS, Durie BG International staging system for multiple myeloma. J. Clin. Oncol. 23(15), 3412\u20133420 (2005).","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"e_1_3_9_45_2","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo A","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 33(26), 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"e_1_3_9_46_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/ejh.13426","article-title":"Impact of performance status on overall survival in patients with relapsed and\/or refractory multiple myeloma: real-life outcomes of daratumumab treatment","volume":"105","author":"Afram G","year":"2020","unstructured":"Afram G, Gran C, Borg Bruchfeld J Impact of performance status on overall survival in patients with relapsed and\/or refractory multiple myeloma: real-life outcomes of daratumumab treatment. Eur. J. Haematol. 105(2), 196\u2013202 (2020).","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"e_1_3_9_47_2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/bjh.13253","article-title":"Renal impairment at presentation in multiple myeloma continues to be associated with poor survival","volume":"169","author":"Laing AA","year":"2015","unstructured":"Laing AA, Geddes C, Soutar R. Renal impairment at presentation in multiple myeloma continues to be associated with poor survival. Brit. J. Haematol. 169(6), 901\u2013902 (2015).","journal-title":"Brit. J. Haematol."},{"issue":"8","key":"e_1_3_9_48_2","doi-asserted-by":"crossref","first-page":"e067966","DOI":"10.1136\/bmjopen-2022-067966","article-title":"Effect modification in network meta-analyses for relapsed\/refractory multiple myeloma: systematic review and meta-analysis","volume":"13","author":"Rose CJ","year":"2023","unstructured":"Rose CJ, Ohm IK, Giske L, N\u00e6ss GE, Fretheim A. Effect modification in network meta-analyses for relapsed\/refractory multiple myeloma: systematic review and meta-analysis. BMJ Open 13(8), e067966 (2023).","journal-title":"BMJ Open"},{"issue":"1","key":"e_1_3_9_49_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41408-024-01109-4","article-title":"Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm","volume":"14","author":"Pawlyn C","year":"2024","unstructured":"Pawlyn C, Schjesvold FH, Cairns DA Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer J. 14(1), 134 (2024).","journal-title":"Blood Cancer J."},{"issue":"3","key":"e_1_3_9_50_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9 J","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 12(3), 45 (2022).","journal-title":"Blood Cancer J."},{"issue":"1","key":"e_1_3_9_51_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah NH","year":"2022","unstructured":"Abdallah NH, Binder M, Rajkumar SV A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 12(1), 21 (2022).","journal-title":"Blood Cancer J."},{"issue":"29","key":"e_1_3_9_52_2","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"D'agostino M","year":"2022","unstructured":"D'agostino M, Cairns DA, Lahuerta JJ Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J. Clin. Oncol. 40(29), 3406\u20133418 (2022).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_9_53_2","unstructured":"NICE. Health Technology Evaluations: The Manual. (2022)."},{"key":"e_1_3_9_54_2","unstructured":"IQWiG. General Methods (Version 6.0 of 5 November 2020). (2020)."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:51:33Z","timestamp":1758797493000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.57264\/cer-2024-0180"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0180","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"e240180"}}